Evidence map›Paper›PMID 28748199›Full record

ArticlePostdoc journal : a journal of postdoctoral research and postdoctoral affairs2015

Current Research Approaches to Target Biofilm Infections.

Erik van Tilburg Bernardes, Shawn Lewenza, Shauna Reckseidler-Zenteno

Abstract read
In one paragraph

Article in Postdoc journal : a journal of postdoctoral research and postdoctoral affairs, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Microbial biofilm: formation, architecture, antibiotic resistance, and control strategies.Brazilian journal of microbiology : [publication of the Brazilian Society for Microbiology] · 2021
    Review
  7. Article
  8. Review
  9. Review
  10. Article
  11. Article
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Erik van Tilburg BernardesDepartment of Microbiology, Immunology, and Infectious Diseases Faculty of Medicine, University of Calgary, Calgary, Alberta, Canada T2N 4N1.
Shawn LewenzaDepartment of Microbiology, Immunology, and Infectious Diseases Faculty of Medicine, University of Calgary, Calgary, Alberta, Canada T2N 4N1.
Shauna Reckseidler-ZentenoDepartment of Microbiology, Immunology, and Infectious Diseases Faculty of Medicine, University of Calgary, Calgary, Alberta, Canada T2N 4N1.

Funding

Novel adjunctive therapy for drug resistant Gram-negative pathogensR33AI098701 · NIAID · UNIVERSITY OF BRITISH COLUMBIA · PI HANCOCK, ROBERT ERNEST WILLIAM · 2014 to 2016
$788k
Novel adjunctive therapy for drug resistant Gram-negative pathogensR21AI098701 · NIAID · UNIVERSITY OF BRITISH COLUMBIA · PI HANCOCK, ROBERT ERNEST WILLIAM · 2012 to 2013
$297k
NIAID NIH HHS R21 AI098701NIAID NIH HHS R33 AI098701
6 · The paper itself

Abstract

This review will focus on strategies to develop new treatments that target the biofilm mode of growth and that can be used to treat biofilm infections. These approaches aim to reduce or inhibit biofilm formation, or to increase biofilm dispersion. Many antibiofilm compounds are not bactericidal but render the cells in a planktonic growth state, which are more susceptible to antibiotics and more easily cleared by the immune system. Novel compounds are being developed with antibiofilm activity that includes antimicrobial peptides, natural products, small molecules and polymers. Bacteriophages are being considered for use in treating biofilms, as well as the use of enzymes that degrade the extracellular matrix polymers to dissolve biofilms. There is great potential in these new approaches for use in treating chronic biofilm infections.

Indexed as

antibiofilm strategiesantimicrobial peptidesbacterial biofilmsdispersalenzyme treatmentsinfectionsmatrix polymerssmall molecule inhibitors

Identifiers

PMID28748199
PMCPMC5524445

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.